Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

Executive Summary

The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.

Advertisement

Related Content

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales
Third Time's The Charm? Orexigen Terminates CONVENE
Novo's Saxenda bags FDA approval for weight management
Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel